KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Short-term Investments (2016 - 2023)

Amgen has reported Short-term Investments over the past 15 years, most recently at $1.0 million for Q1 2023.

  • For Q1 2023, Short-term Investments fell 93.75% year-over-year to $1.0 million; the TTM value through Mar 2023 reached $1.0 million, down 93.75%, while the annual FY2022 figure was $1.7 billion, 3391.67% up from the prior year.
  • Short-term Investments for Q1 2023 was $1.0 million at Amgen, down from $1.7 billion in the prior quarter.
  • Over five years, Short-term Investments peaked at $18.9 billion in Q1 2019 and troughed at $1.0 million in Q1 2023.
  • A 5-year average of $4.1 billion and a median of $2.0 billion in 2022 define the central range for Short-term Investments.
  • On a YoY basis, Short-term Investments climbed as much as 3391.67% in 2022 and fell as far as 99.64% in 2022.
  • Year by year, Short-term Investments stood at $2.9 billion in 2019, then surged by 52.44% to $4.4 billion in 2020, then crashed by 98.9% to $48.0 million in 2021, then skyrocketed by 3391.67% to $1.7 billion in 2022, then tumbled by 99.94% to $1.0 million in 2023.
  • Business Quant data shows Short-term Investments for AMGN at $1.0 million in Q1 2023, $1.7 billion in Q4 2022, and $2.0 billion in Q3 2022.